All In Biotech

NDA 017812 · Hikma

Lithium Carbonate

Lithium Carbonate · Oral

Last checked: Nov 20, 2026Latest source record: Oct 13, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1980

Nov 26, 1980

Approved uses

1

Original approval plus efficacy supplements

Registered trials

246

60 Phase 3, 15 recruiting

FAERS reports

16,493

13,263 serious, 1,210 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LITHIUM TOXICITY Lithium toxicity is closely related to serum lithium concentrations, and can occur at doses close to therapeutic concentrations. Facilities for prompt and accurate serum lithium determinations should be available before initiating treatment [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5.1 )] . WARNING: LITHIUM TOXICITY See full prescribing information for complete boxed warning. Lithium toxicity is closely related to serum lithium concentrations, and can occur at doses close to therapeutic concentrations. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy ( 2.3 , 5.1 ).

What it is approved for

From the label in effect Oct 16, 2026.

Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder: Treatment of acute manic and mixed episodes in patients 7 years and older [see Clinical Studies ( 14 )] Maintenance treatment in patients 7 years and older [see Clinical Studies ( 14 )] Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder: Treatment of acute manic and mixed episodes in patients 7 years and older ( 1 ) Maintenance treatment in patients 7 years and older ( 1 )

Mechanism: The mechanism of action of lithium as a mood stabilizing agent is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 26, 1980 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • LITHIUM CARBONATE · LITHIUM CARBONATE 150MG · CAPSULE, ORAL · Prescription · TE AB
  • LITHIUM CARBONATE · LITHIUM CARBONATE 600MG · CAPSULE, ORAL · Prescription · TE AB
  • LITHIUM CARBONATE · LITHIUM CARBONATE 300MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lithium Carbonate" as an intervention, any sponsor and status, largest first.

All 246 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • toxicity to various agents1,246
  • drug ineffective1,124
  • tremor1,066
  • drug interaction999
  • nausea811
  • weight increased794
  • insomnia698
  • depression693
  • fatigue671
  • vomiting663
  • confusional state636
  • somnolence627

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004530
2005452
2006746
20071,023
2008723
2009826
2010798
20111,114
20121,406
2013499
2014398
2015615
2016694
2017584
2018717
2019677
2020687
2021762
2022740
2023723
2024654
2025594
2026531

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lithium Carbonate (Lithium Carbonate)

2024 spending

$7.1M

Beneficiaries

101,068

724,316 claims

Per beneficiary

$71

$0.14 per unit

View as table
YearSpending
2020$7,937,834
2021$7,501,144
2022$7,074,281
2023$7,437,848
2024$7,127,156

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 393 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.